BR112014032049A2 - citrato férrico e suplemento de ferro oral - Google Patents

citrato férrico e suplemento de ferro oral

Info

Publication number
BR112014032049A2
BR112014032049A2 BR112014032049A BR112014032049A BR112014032049A2 BR 112014032049 A2 BR112014032049 A2 BR 112014032049A2 BR 112014032049 A BR112014032049 A BR 112014032049A BR 112014032049 A BR112014032049 A BR 112014032049A BR 112014032049 A2 BR112014032049 A2 BR 112014032049A2
Authority
BR
Brazil
Prior art keywords
ferric citrate
iron supplement
oral iron
oral
supplement
Prior art date
Application number
BR112014032049A
Other languages
English (en)
Inventor
Poradosu Enrique
F Oliviero James Iii
Bentsur Ron
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of BR112014032049A2 publication Critical patent/BR112014032049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014032049A 2012-06-21 2013-06-21 citrato férrico e suplemento de ferro oral BR112014032049A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Publications (1)

Publication Number Publication Date
BR112014032049A2 true BR112014032049A2 (pt) 2017-07-25

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032049A BR112014032049A2 (pt) 2012-06-21 2013-06-21 citrato férrico e suplemento de ferro oral

Country Status (17)

Country Link
US (3) US20130345303A1 (pt)
EP (3) EP2863906B1 (pt)
JP (4) JP2015535209A (pt)
KR (2) KR20200103855A (pt)
CN (2) CN113244209A (pt)
AU (2) AU2013278000A1 (pt)
BR (1) BR112014032049A2 (pt)
CA (1) CA2876982A1 (pt)
DK (1) DK3730136T3 (pt)
EA (1) EA201590062A1 (pt)
ES (2) ES2970050T3 (pt)
HK (2) HK1210013A1 (pt)
IL (1) IL236356A0 (pt)
MX (1) MX2014015615A (pt)
PL (1) PL3730136T3 (pt)
SG (2) SG10201805177PA (pt)
WO (1) WO2013192565A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573807A (zh) 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
DK3578185T3 (da) 2013-06-05 2020-11-02 Tricida Inc Protonbindende polymerer til oral indgivelse
EP2856941B1 (en) * 2013-10-01 2020-11-25 Fresenius Medical Care Deutschland GmbH Method and apparatuses for determining a patient's daily loss of iron
JP2016535780A (ja) * 2013-11-04 2016-11-17 ケリク バイオファーマシューティカルス， インコーポレーテッド 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
EP3593808B1 (en) 2014-12-10 2020-12-09 Tricida Inc. Proton-binding polymers for oral administration
KR20170123664A (ko) * 2015-03-04 2017-11-08 케릭스 바이오파마슈티컬스 인코포레이티드 철-결핍성 빈혈의 치료에서 구연산철의 용도
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US20210085711A1 (en) 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
BR112021008142A2 (pt) * 2018-10-29 2021-08-03 Pharmacosmos Holding A/S tratamento de deficiência de ferro com carboximaltose férrica
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003185A1 (fr) * 1996-07-19 1998-01-29 Nikken Chemicals Co., Ltd. Remedes contre l'hyperphosphatemie
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
CA3050453C (en) 2005-08-18 2021-07-27 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20180077337A (ko) * 2006-01-06 2018-07-06 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
HUE028029T2 (en) 2006-01-30 2016-11-28 Panion & Bf Biotech Inc A method of treating chronic kidney disease
CN102573807A (zh) * 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型

Also Published As

Publication number Publication date
IL236356A0 (en) 2015-02-26
HK1214503A1 (zh) 2016-07-29
JP2022070945A (ja) 2022-05-13
US20130345303A1 (en) 2013-12-26
KR20150036131A (ko) 2015-04-07
EP4335436A3 (en) 2024-05-15
CA2876982A1 (en) 2013-12-27
US20140234416A1 (en) 2014-08-21
WO2013192565A3 (en) 2015-10-15
JP2020100638A (ja) 2020-07-02
EP2863906B1 (en) 2020-03-18
EP3730136A1 (en) 2020-10-28
JP2018138562A (ja) 2018-09-06
JP2015535209A (ja) 2015-12-10
ES2796254T3 (es) 2020-11-26
SG10201805177PA (en) 2018-07-30
WO2013192565A2 (en) 2013-12-27
AU2018203205B2 (en) 2020-03-12
EA201590062A1 (ru) 2016-02-29
EP4335436A2 (en) 2024-03-13
KR102150135B1 (ko) 2020-08-31
AU2018203205A1 (en) 2018-05-31
EP2863906A2 (en) 2015-04-29
US20150079168A1 (en) 2015-03-19
CN113244209A (zh) 2021-08-13
DK3730136T3 (da) 2024-01-22
ES2970050T3 (es) 2024-05-24
MX2014015615A (es) 2015-03-20
CN104884055A (zh) 2015-09-02
EP3730136B1 (en) 2023-12-27
AU2013278000A1 (en) 2015-01-22
KR20200103855A (ko) 2020-09-02
PL3730136T3 (pl) 2024-03-25
SG11201408521WA (en) 2015-01-29
HK1210013A1 (en) 2016-04-15

Similar Documents

Publication Publication Date Title
BR112014032049A2 (pt) citrato férrico e suplemento de ferro oral
HK1209413A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof 5--2-
HK1203493A1 (en) Substituted azabicycles and use thereof
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
EP2751270A4 (en) OLIGOMER CONJUGATE COMPLEXES AND ITS USE
BR302013001611S1 (pt) Configuração aplicada em ferro de passar
IL251974B (en) Antifibrosis compounds and their uses
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
BR112013003053A2 (pt) ferro de passar
GB201216649D0 (en) Agents and methods
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
BR112014000255A2 (pt) composição de suplemento de ferro
HK1212166A1 (en) Citrate rich calcium magnesium supplement and uses thereof
EP2816127A4 (en) CAST IRON AND BRAKE PART
EP2864345A4 (en) NUCLEIC ACID PARTICLE CONJUGATES AND THERAPEUTIC APPLICATIONS THEREOF
GB2503963C (en) Patient garment
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
PL2830587T3 (pl) Kompozycja o balansującym i ochronnym wpływie na skórę
FR2992526B1 (fr) Protege-col et protege-aisselles des chemises
EP2837938A4 (en) C1Q-ADIPONECTIN COMPLEX AND USE THEREOF
EP2922862A4 (en) COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF
FI10259U1 (fi) Kaislarauta
AP2015008228A0 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2675 DE 12-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.